NCT07905950
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
the complete response (CR) rate assessed at the end of Cycle 4 or Cycle 8
Timeframe: at the end of Cycle 4 or Cycle 8(each cycle is 21 days).
Secondary (9)
The 3-year event-free survival (EFS) rate
3-year overall survival (OS) rate
The median event-free survival (mEFS)
The median overall survival (mOS)
The local recurrence rate (LRR)
Show 4 moreShow less
R0 resection rate
distant metastasis rate (DM)
The organ preservation rate
incidence of adverse events (AEs)
Arms and interventions
treatment armExperimental
Drugs: Adebrelimab
Sites
1 site in 1 country
- Henan Cancer HospitalZhengzhou, Henan, China